Medication adherence following pharmacogenomic testing in patients with major depressive disorder.

Andria Del Tredici¹, Holly L Johnson¹, W Brady DeHart², Alexander Gutin¹, Katherine Johansen Taber¹, Pamela Morin², Laura Becker², Devika Chawla³, Andrew A Nierenberg⁴

¹Myriad Genetics Inc, Salt Lake City, UT, USA.

²Optum, Eden Prairie, MN, USA.

³Myriad Genetics Inc, Salt Lake City, UT, USA. Electronic address: Devika.chawla@myriad.com.

⁴Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.

PubMed DOI

Abstract

OBJECTIVE: Approximately 50% of patients with major depressive disorder (MDD) prematurely discontinue their antidepressant medication within 6 months, increasing risk of relapse. Pharmacogenomic (PGx) testing may improve medication adherence by informing treatment based on gene-drug interactions (GDI). Here, we evaluated whether PGx informed treatmentimproved medication adherence in MDD patients.…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.